Improved IgG3 levels and reduced infection rate in a woman with CVID switched from intravenous to subcutaneous immunoglobulin therapy

Immunotherapy

Volumn 4, Issue 12, 2012, Pages 1835-1839

  Shapiro, Ralph S ^a  

^a Midwest Immunology Clinic   (United States)

Author keywords

common variable immune deficiency; IgG subclass deficiency; intravenous immunoglobulin therapy; primary immune deficiency diseases; subcutaneous immunoglobulin therapy

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G3;

ABNORMAL RESPIRATORY SOUND; ADULT; AIRWAY OBSTRUCTION; ARTICLE; BRONCHITIS; CASE REPORT; COMMON VARIABLE IMMUNODEFICIENCY; COUGHING; DRUG DOSE INCREASE; EARDRUM DISEASE; EYE INFLAMMATION; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; LUNG CONGESTION; LUNG INFECTION; MEDICAL CARE; MORBIDITY; PRIORITY JOURNAL; RECURRENT INFECTION; SINUSITIS; SKULL DISEASE; SMALL AIRWAY DISEASE;

ADULT; BIOMARKERS, PHARMACOLOGICAL; CLINICAL PROTOCOLS; COMMON VARIABLE IMMUNODEFICIENCY; DRUG SUBSTITUTION; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; RECURRENCE; RESPIRATORY TRACT INFECTIONS;

EID: 84871204549     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.130     Document Type: Article

References (30)

1. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allergy Clin. North Am. 28, 803-819 (2008).
2. Alyanakian MA, Bernatowska E, Scherrmann JM et al. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang. 84, 188-192 (2003).
3. Berger M, Pinciaro PJ, Flebogamma 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J. Clin. Immunol. 24, 389-396 (2004).
4. Vivaglobin®, package insert. CSL Behring LLC, IL, USA.
5. Al-Herz W, Bousfiha A, Casanova JL et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front. Immunol. 2, 54 (2011).
6. Berger M. l-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use. Immunotherapy 3, 163-176 (2011).
7. Berger M. Subcutaneous administration of IgG. Immunol. Allergy Clin. N. Am. 28, 779-802 (2008).
8. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin. Immunol. 112, 1-7 (2004).
9. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49, 673-680 (1970).
10. Björkander J, Nikoskelainen J, Leibl H et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo-or agammaglobulinemia. Vox Sang. 90, 286-293 (2006).
11. Mankarious S, Lee M, Fischer S et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J. Lab. Clin. Med. 112, 634-640 (1988).
12. Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective deficiency: response to intravenous immunoglobulin therapy. Clin. Exp. Immunol. 159, 344-350 (2009).
13. Jefferis R, Kumararatne DS. Selective IgG subclass deficiency: quantification and clinical relevance. Clin. Exp. Immunol. 81, 357-367 (1990).
14. Naegel GP, Young KR Jr, Reynolds HY. Receptors for human IgG subclasses on human alveolar macrophages. Am. Rev. Respir. Dis. 129, 413-418 (1984).
15. Meyts I, Bossuyt X, Proesmans M, De B. Isolated IgG3 deficiency in children: to treat or not to treat? Case presentation and review of the literature. Pediatr. Allergy Immunol. 17, 544-550 (2006).
16. Shapiro GG, Virant FS, Furukawa CT et al. Immunologic defects in patients with refractory sinusitis. Pediatrics 87, 311-316 (1991).
17. Armenaka M, Grizzanti J, Rosenstreich DL. Serum immunoglobulins and IgG subclass levels in adults with chronic sinusitis: evidence for decreased IgG3 levels. Ann. Allergy 72, 507-514 (1994).
18. Vanlerberghe L, Joniau S, Jorissen M. The prevalence of humoral immunodeficiency in refractory rhinosinusitis: a retrospective analysis. B-ENT 2, 161-166 (2006).
19. Ozkan H, Atlihan F, Genel F et al. IgA and/or IgG subclass deficiency in children with recurrent respiratory infections and its relationship with chronic pulmonary damage. J. Investig. Allergol. Clin. Immunol. 15, 69-74 (2005).
20. Barlan IB, Geha RS, Schneider LC. Therapy for patients with recurrent infections and low serum IgG3 levels. J. Allergy Clin. Immunol. 92, 353-355 (1993).
21. Bayry J, Fournier EM, Maddur MS et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J. Autoimmun. 36, 9-15 (2011).
22. Imbach P. 30 years of immunomodulation by intravenous immunoglobulin. Immunotherapy 4, 651-654 (2012).
23. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin. Exp. Immunol. 164(Suppl. 2), 2-5 (2011).
24. Schiff RI. Individualizing the dose of intravenous immune serum globulin for therapy of patients with primary humoral immunodeficiency. Vox Sang. 49(Suppl. 1), 15-24 (1985).
25. Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117(Suppl.), S525-S553 (2006).
26. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy Clin. Immunol. 125, 1354-1360.e4 (2010).
27. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-Analysis of clinical studies. Clin. Immunol. 137, 21-30 (2010).
28. Radinsky S, Bonagura VR. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J. Allergy Clin. Immunol. 112, 630-633 (2003).
29. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J. Allergy Clin. Immunol. 122, 210-212 (2008).
30. Immune Globulin. Yahoo! Health, licensed from American Hospital Formulary Service Drug Information. http://health.yahoo.net/ahfscontent/immune-globulin/ 6?brand=Baygam (Accessed 18 April 2012)